Dermatology

This new Q&A interview with Dr. Cotton featured a discussion on the issues facing pediatric HS patients and other topics covered in her upcoming SHSA Conference presentation.

This new research was prospectively gathered in Denmark and involved nationwide, population-based data as well as a uniform approach to melanoma treatment and surveillance.

A population-based cohort study highlighted an association between AD and IBD with risk varying by age, AD severity, and subtype of IBD.

This systematic review highlighted the rise in studies on artificial intelligence and teledermatology for skin cancer, as well as other gaps in related research.

Ashfaq Marghoob, MD, discusses his recent workshop presentation on dermoscopies for skin cancer.

This new research highlights the advantages of patients with chronic spontaneous urticaria adhering to a daily maintenance non-sedating antihistamine schedule.

This new data indicates that this not widely-practiced surgery for MCC, while effective, may first require initial implementation at higher-volume, regional centers for MCC due to existing infrastructure.

This new data is consistent with previous results on efficacy and on safety shown in global phase 3 studies that had enrolled both adults and adolescents.

This new research letter highlights several trends in prescribing by both dermatologists and non-dermatologists from 2017 to 2020.

In this Q&A interview with Dr. Rieder, he describes the biggest takeaways from his panel discussion on the mental health needs of dermatology patients.

This segment of Dr. Eichenfield’s interview featured a discussion about Eichenfield’s response to the FDA’s approval of cantharadin 0.7%, or VP-102, for molluscum contagiosum.

In his latest recorded interview, Dr. Eichenfield described the use of VP-102, or cantharidin 0.7%, for molluscum contagiosum.

This new data highlights the lack of reliability with regard to medical information disseminated on social media platforms, and the frequency at which such information is observed.

This new data from China showed that both the duration of mask-wearing and greater use of facial cleansing may result in skin deterioration, though moisturizing products were found to have more positive effects.

This analysis demonstrated the efficacy of topical azelaic acid, though further randomized control trial evidence may be needed for an evaluation of the treatment on skin aging.

The results of this analysis indicated that while improvement was seen in both groups, slight dermoscopy score improvement was observed in those given a combination laser-minoxidil treatment compared to only minoxidil.

This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.

Gina Mangin, MPAS, PA-C, shares take-home pearls with fellow healthcare providers, highlighting the importance of listening to the patient.

An expert in dermatological conditions discusses new treatments in the pipeline for HS, commenting on her experience with biologic treatment.

Gina Mangin, MPAS, PA-C, reviews current treatment options for patients with HS, highlighting adalimumab as well as non-FDA approved therapies.

In this recent analysis of hyperhidrosis burden on patients, prevalence of the condition and its impacts on patients demonstrate the value of exploring knowledge gaps for this disease.

An expert physician assistant in dermatology provides an overview of how HS is diagnosed, and how the diagnosis is often delayed.

Gina Mangin, MPAS, PA-C, reviews the quality of life for patients living with hidradenitis suppurativa (HS), areas of the body commonly affected by HS, as well as the most common symptoms of the disease.

An expert in dermatological conditions discusses office-based procedures that can benefit patients with HS and shares clinical pearls for the management of the disorder.

Andrew Baker PA-C, MBA, reviews unmet needs for the clinical management of moderate-to-severe HS and shares insight on novel and emerging therapies in the pipeline.